Skip to main
PTHS
PTHS logo

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics Inc. is demonstrating a significant uptick in financial performance, with revised 4Q net revenue projections increasing from $4.5 million to $16.2 million, bolstered by over 40% growth in unit prescriptions from the previous month. The expansion of its sales force from 50 to 64 personnel indicates a strategic focus on capturing new market opportunities, as management aims to grow their target accounts from 8,000 to 10,000. Additionally, the successful launch of ZELSUVMI, generating net revenues of $7.1 million, reflects strong initial market traction and effective product positioning, further enhancing the company's growth prospects.

Bears say

Pelthos Therapeutics Inc faces significant challenges that could negatively impact its stock performance, primarily concerning financial resource management for product development and commercialization. Risks related to patent protection expose the company to potential generic competition while delays or adverse outcomes from clinical studies could further hinder its pipeline progress. Additionally, fluctuations in regulatory policies, reimbursement environments, and increasing competition from other companies within the same therapeutic market underscore the precarious position of Pelthos Therapeutics in the biotechnology sector.

PTHS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Strong Buy based on their latest research and market trends.

According to 4 analysts, PTHS has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.